vs
Side-by-side financial comparison of FRESH DEL MONTE PRODUCE INC (FDP) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
FRESH DEL MONTE PRODUCE INC is the larger business by last-quarter revenue ($1.0B vs $708.5M, roughly 1.4× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 3.2%, a 15.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 0.6%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-17.2M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -4.1%).
Fresh Del Monte Produce Incorporated is one of the world’s leading vertically integrated producers, distributors, and marketers of prepared, fresh and fresh-cut fruits and vegetables. Incorporated in George Town, Cayman Islands, its US executive office is located at 241 Sevilla Avenue, Coral Gables, Florida.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
FDP vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $708.5M |
| Net Profit | $32.3M | $135.1M |
| Gross Margin | 10.4% | — |
| Operating Margin | 4.5% | 21.6% |
| Net Margin | 3.2% | 19.1% |
| Revenue YoY | 0.6% | 32.0% |
| Net Profit YoY | 59.1% | 15.5% |
| EPS (diluted) | $0.67 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $708.5M | ||
| Q3 25 | $1.0B | $659.9M | ||
| Q2 25 | $1.2B | $603.3M | ||
| Q1 25 | $1.1B | $558.6M | ||
| Q4 24 | $1.0B | $536.6M | ||
| Q3 24 | $1.0B | $533.3M | ||
| Q2 24 | $1.1B | $528.1M | ||
| Q1 24 | $1.1B | $511.0M |
| Q4 25 | $32.3M | $135.1M | ||
| Q3 25 | $-29.1M | $111.1M | ||
| Q2 25 | $56.8M | $90.3M | ||
| Q1 25 | $31.1M | $114.6M | ||
| Q4 24 | $20.3M | $117.0M | ||
| Q3 24 | $42.1M | $96.4M | ||
| Q2 24 | $53.6M | $88.4M | ||
| Q1 24 | $26.1M | $102.6M |
| Q4 25 | 10.4% | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 9.9% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 4.5% | 21.6% | ||
| Q3 25 | -2.1% | 21.5% | ||
| Q2 25 | 5.8% | 20.9% | ||
| Q1 25 | 4.1% | 20.3% | ||
| Q4 24 | 3.0% | 23.4% | ||
| Q3 24 | 5.3% | 21.1% | ||
| Q2 24 | 6.0% | 19.9% | ||
| Q1 24 | 4.0% | 20.4% |
| Q4 25 | 3.2% | 19.1% | ||
| Q3 25 | -2.8% | 16.8% | ||
| Q2 25 | 4.8% | 15.0% | ||
| Q1 25 | 2.8% | 20.5% | ||
| Q4 24 | 2.0% | 21.8% | ||
| Q3 24 | 4.1% | 18.1% | ||
| Q2 24 | 4.7% | 16.7% | ||
| Q1 24 | 2.4% | 20.1% |
| Q4 25 | $0.67 | $4.65 | ||
| Q3 25 | $-0.61 | $3.86 | ||
| Q2 25 | $1.18 | $3.10 | ||
| Q1 25 | $0.64 | $3.67 | ||
| Q4 24 | $0.41 | $3.67 | ||
| Q3 24 | $0.88 | $3.01 | ||
| Q2 24 | $1.12 | $2.75 | ||
| Q1 24 | $0.55 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $35.7M | $497.0M |
| Total DebtLower is stronger | $176.2M | — |
| Stockholders' EquityBook value | $2.0B | $459.1M |
| Total Assets | $3.1B | $2.0B |
| Debt / EquityLower = less leverage | 0.09× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.7M | $497.0M | ||
| Q3 25 | $97.2M | $285.4M | ||
| Q2 25 | $85.5M | $46.3M | ||
| Q1 25 | $34.4M | $441.4M | ||
| Q4 24 | $32.6M | $669.4M | ||
| Q3 24 | $50.8M | $656.9M | ||
| Q2 24 | $37.8M | $510.9M | ||
| Q1 24 | $42.2M | $407.0M |
| Q4 25 | $176.2M | — | ||
| Q3 25 | $176.7M | — | ||
| Q2 25 | $205.2M | — | ||
| Q1 25 | $237.4M | — | ||
| Q4 24 | $248.9M | — | ||
| Q3 24 | $274.8M | — | ||
| Q2 24 | $290.4M | — | ||
| Q1 24 | $405.8M | — |
| Q4 25 | $2.0B | $459.1M | ||
| Q3 25 | $2.0B | $293.6M | ||
| Q2 25 | $2.1B | $172.4M | ||
| Q1 25 | $2.0B | $593.6M | ||
| Q4 24 | $2.0B | $825.5M | ||
| Q3 24 | $2.0B | $881.4M | ||
| Q2 24 | $2.0B | $763.6M | ||
| Q1 24 | $1.9B | $671.5M |
| Q4 25 | $3.1B | $2.0B | ||
| Q3 25 | $3.1B | $1.8B | ||
| Q2 25 | $3.2B | $1.6B | ||
| Q1 25 | $3.2B | $1.9B | ||
| Q4 24 | $3.1B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.1B | $1.9B | ||
| Q1 24 | $3.2B | $1.8B |
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.09× | — | ||
| Q2 25 | 0.10× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.21× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.9M | $192.7M |
| Free Cash FlowOCF − Capex | $-17.2M | $188.1M |
| FCF MarginFCF / Revenue | -1.7% | 26.6% |
| Capex IntensityCapex / Revenue | 2.8% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.34× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $181.3M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.9M | $192.7M | ||
| Q3 25 | $75.0M | $246.2M | ||
| Q2 25 | $113.1M | $148.5M | ||
| Q1 25 | $46.1M | $125.8M | ||
| Q4 24 | $-4.7M | $190.7M | ||
| Q3 24 | $43.5M | $149.1M | ||
| Q2 24 | $125.0M | $116.4M | ||
| Q1 24 | $18.7M | $152.7M |
| Q4 25 | $-17.2M | $188.1M | ||
| Q3 25 | $60.9M | $235.5M | ||
| Q2 25 | $101.5M | $142.4M | ||
| Q1 25 | $36.1M | $115.8M | ||
| Q4 24 | $-22.3M | $183.0M | ||
| Q3 24 | $30.1M | $138.5M | ||
| Q2 24 | $117.0M | $103.5M | ||
| Q1 24 | $6.0M | $147.2M |
| Q4 25 | -1.7% | 26.6% | ||
| Q3 25 | 6.0% | 35.7% | ||
| Q2 25 | 8.6% | 23.6% | ||
| Q1 25 | 3.3% | 20.7% | ||
| Q4 24 | -2.2% | 34.1% | ||
| Q3 24 | 3.0% | 26.0% | ||
| Q2 24 | 10.3% | 19.6% | ||
| Q1 24 | 0.5% | 28.8% |
| Q4 25 | 2.8% | 0.6% | ||
| Q3 25 | 1.4% | 1.6% | ||
| Q2 25 | 1.0% | 1.0% | ||
| Q1 25 | 0.9% | 1.8% | ||
| Q4 24 | 1.7% | 1.4% | ||
| Q3 24 | 1.3% | 2.0% | ||
| Q2 24 | 0.7% | 2.4% | ||
| Q1 24 | 1.1% | 1.1% |
| Q4 25 | 0.34× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 1.99× | 1.65× | ||
| Q1 25 | 1.48× | 1.10× | ||
| Q4 24 | -0.23× | 1.63× | ||
| Q3 24 | 1.03× | 1.55× | ||
| Q2 24 | 2.33× | 1.32× | ||
| Q1 24 | 0.72× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDP
| Other | $482.7M | 47% |
| Gold Pineapples | $184.9M | 18% |
| Fresh Cut Fruit | $126.4M | 12% |
| Fresh Cut Vegetables | $69.3M | 7% |
| Avocados | $66.9M | 7% |
| Other Fruit Productsand Services | $26.1M | 3% |
| Non Tropical Fruit | $23.0M | 2% |
| Melons | $20.6M | 2% |
| Vegetables | $19.6M | 2% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
